Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice

Foth, M. et al. (2014) Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. Journal of Pathology, 233(2), pp. 148-158. (doi: 10.1002/path.4334)

94632.pdf - Accepted Version



Although somatic mutations and overexpression of the tyrosine kinase fibroblast growth factor receptor 3 (FGFR3) are strongly associated with bladder cancer, evidence for their functional involvement in the pathogenesis remains elusive. Previously we showed that activation of Fgfr3 alone is not sufficient to initiate urothelial tumourigenesis in mice. Here we hypothesize that cooperating mutations are required for Fgfr3-dependent tumourigenesis in the urothelium and analyse a mouse model in which an inhibitor of Pi3k–Akt signalling, Pten, is deleted in concert with Fgfr3 activation (UroIICreFgfr3+/K644EPtenflox/flox). Two main phenotypical characteristics were observed in the urothelium: increased urothelial thickness and abnormal cellular histopathology, including vacuolization, condensed cellular appearance, enlargement of cells and nuclei, and loss of polarity. These changes were not observed when either mutation was present individually. Expression patterns of known urothelial proteins indicated the abnormal cellular differentiation. Furthermore, quantitative analysis showed that Fgfr3 and Pten mutations cooperatively caused cellular enlargement, while Pten contributed to increased cell proliferation. Finally, FGFR3 overexpression was analysed along the level of phosphorylated mTOR in 66 T1 urothelial tumours in tissue microarray, which supported the occurrence of functional association of these two signalling pathways in urothelial pathogenesis. Taken together, this study provides evidence supporting a functional role of FGFR3 in the process of pathogenesis in urothelial neoplasms. Given the wide availability of inhibitors specific to FGF signalling pathways, our model may open the avenue for FGFR3-targeted translation in urothelial disease. Copyright © 2014 Pathological Society of Great Britain and Ireland.

Item Type:Articles
Additional Information:This is the accepted version of the following article: Journal of Pathology 233(2):148-158 2014, which has been published in final form at
Glasgow Author(s) Enlighten ID:Ahmad, Mr Imran and Ridgway, Dr Rachel and Iwata, Dr Tomoko and Leung, Professor Hing and Sansom, Professor Owen
Authors: Foth, M., Ahmad, I., van Rhijn, B. W., van der Kwast, T., Bergman, A. M., King, L., Ridgway, R., Leung, H. Y., Fraser, S., Sansom, O. J., and Iwata, T.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Journal of Pathology
Publisher:John Wiley & Sons, Ltd.
ISSN (Online):1096-9896
Copyright Holders:Copyright © 2014 Pathological Society of Great Britain and Ireland
First Published:First published in the Journal of Pathology 233(2):148-158
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record